Surgery Partners, Inc. (NASDAQ:SGRY) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Surgery Partners, Inc. (NASDAQ:SGRY - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $43.63.

A number of brokerages recently issued reports on SGRY. Cantor Fitzgerald reiterated an "overweight" rating and issued a $43.00 price objective on shares of Surgery Partners in a report on Tuesday, March 5th. Barclays began coverage on shares of Surgery Partners in a report on Wednesday, March 6th. They set an "equal weight" rating and a $35.00 price target for the company. StockNews.com upgraded shares of Surgery Partners from a "sell" rating to a "hold" rating in a report on Thursday, March 21st. Citigroup lowered their price target on shares of Surgery Partners from $43.00 to $42.00 and set a "buy" rating for the company in a report on Tuesday, February 27th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $49.00 price target on shares of Surgery Partners in a report on Thursday, February 29th.

Surgery Partners Price Performance

Shares of SGRY traded down $0.09 during mid-day trading on Monday, reaching $27.35. The company had a trading volume of 503,135 shares, compared to its average volume of 906,445. The company's 50 day simple moving average is $30.67 and its 200 day simple moving average is $30.09. Surgery Partners has a 1-year low of $22.05 and a 1-year high of $45.79. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.57 and a current ratio of 1.71. The company has a market capitalization of $3.46 billion, a price-to-earnings ratio of -273.50, a P/E/G ratio of 2.43 and a beta of 2.71.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.37 by $0.07. Surgery Partners had a negative net margin of 0.43% and a positive return on equity of 3.65%. The company had revenue of $735.40 million for the quarter, compared to the consensus estimate of $741.93 million. During the same period last year, the company posted $0.22 EPS. The firm's quarterly revenue was up 4.0% compared to the same quarter last year. Analysts expect that Surgery Partners will post 0.81 EPS for the current year.

Insider Activity

In other news, CEO Jason Eric Evans sold 5,780 shares of Surgery Partners stock in a transaction on Monday, February 12th. The shares were sold at an average price of $35.08, for a total value of $202,762.40. Following the completion of the sale, the chief executive officer now owns 419,118 shares in the company, valued at approximately $14,702,659.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Surgery Partners news, CFO David T. Doherty sold 1,020 shares of Surgery Partners stock in a transaction on Monday, February 12th. The shares were sold at an average price of $34.93, for a total transaction of $35,628.60. Following the transaction, the chief financial officer now directly owns 74,209 shares of the company's stock, valued at approximately $2,592,120.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jason Eric Evans sold 5,780 shares of Surgery Partners stock in a transaction on Monday, February 12th. The stock was sold at an average price of $35.08, for a total transaction of $202,762.40. Following the transaction, the chief executive officer now directly owns 419,118 shares in the company, valued at $14,702,659.44. The disclosure for this sale can be found here. Insiders sold 18,774 shares of company stock worth $608,352 in the last quarter. 2.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Surgery Partners

A number of hedge funds have recently bought and sold shares of the company. Lazard Asset Management LLC purchased a new position in shares of Surgery Partners in the 2nd quarter worth about $27,000. Stonebridge Capital Advisors LLC purchased a new position in shares of Surgery Partners in the 2nd quarter worth about $45,000. PNC Financial Services Group Inc. boosted its holdings in shares of Surgery Partners by 85.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,033 shares of the company's stock worth $29,000 after buying an additional 476 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Surgery Partners by 187.1% in the 1st quarter. Tower Research Capital LLC TRC now owns 1,229 shares of the company's stock worth $42,000 after buying an additional 801 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new position in shares of Surgery Partners in the 3rd quarter worth about $39,000.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.